ホーム>>Signaling Pathways>> Neuroscience>> Neurokinin Receptor>>Fosaprepitant

Fosaprepitant

カタログ番号GC16246

Fosaprepitant (L-785298) は、Aprepitant のプロドラッグです。

Products are for research use only. Not for human use. We do not sell to patients.

Fosaprepitant 化学構造

Cas No.: 172673-20-0

サイズ 価格 在庫数 個数
10mM (in 1mL DMSO)
$130.00
在庫あり
5mg
$70.00
在庫あり
10mg
$121.00
在庫あり
25mg
$246.00
在庫あり
50mg
$371.00
在庫あり

Tel:(909) 407-4943 Email: sales@glpbio.com

顧客レビュー

カスタマーレビューに基づきます。

  • GlpBio Citations

    GlpBio Citations
  • Bioactive Compounds Premium Provider

    Bioactive Compounds Premium Provider

Sample solution is provided at 25 µL, 10mM.

Description Chemical Properties Product Documents Related Products

Fosaprepitant (L-758,298 MK-0517) is an antagonist of neurokinin-1[1].

Fosaprepitant has shown the pharmacodynamic function by its active metabolite aprepitant. Fosaprepitanot has been found to be a highly selective antagonist of the NK-1 receptor and inhibit the cation of substance P. In addition, Fosaprepitant has been exhibited to have the effect on cisplatin induced emesis in the classical ferret model. Besides, because of the brain penetrating of aprepitant, Fosaprepitant has been revealed to have a very high affinity for the NK-1 receptor and increase the efficacy by dexamethasone, granisetron and so on. Fosaprepitant has been evaluated to use in the prevention of chemotherapy-induced nausea and vomiting (CINV) by combination with a 5-HT3 antagonist and a steroid [1].

References:
[1] Van Belle SJ1, Cocquyt V. Fosaprepitant dimeglumine (MK-0517 or L-785,298), an intravenous neurokinin-1 antagonist for the prevention of chemotherapy induced nausea and vomiting.Expert Opin Pharmacother. 2008 Dec; 9(18):3261-70.

レビュー

Review for Fosaprepitant

Average Rating: 5 ★★★★★ (Based on Reviews and 36 reference(s) in Google Scholar.)

5 Star
100%
4 Star
0%
3 Star
0%
2 Star
0%
1 Star
0%
Review for Fosaprepitant

GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.

Required fields are marked with *

You may receive emails regarding this submission. Any emails will include the ability to opt-out of future communications.